Cargando…

Is There an Epigenetic Component Underlying the Resistance of Triple-Negative Breast Cancers to Parp Inhibitors?

Poly(ADP-ribose) polymerase (Parp) is an enzyme responsible for catalyzing post-translational modifications through the addition of poly(ADP-ribose) chains (known as PARylation). Modification by PARylation modulates numerous cellular processes including transcription, chromatin remodeling, apoptosis...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lovato, Amanda, Panasci, Lawrence, Witcher, Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2012
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3530734/ https://www.ncbi.nlm.nih.gov/pubmed/23293602 http://dx.doi.org/10.3389/fphar.2012.00202

Ejemplares similares

Simultaneous inhibition of ATR and PARP sensitizes colon cancer cell lines to irinotecan
por: Abu-Sanad, Atlal, et al.
Publicado: (2015)

New Perspectives for Resistance to PARP Inhibitors in Triple-Negative Breast Cancer
por: Han, Ye, et al.
Publicado: (2020)

p66ShcA potentiates the cytotoxic response of triple-negative breast cancers to PARP inhibitors
por: Cañedo, Eduardo Cepeda, et al.
Publicado: (2021)

Resistance to PARP-Inhibitors in Cancer Therapy
por: Montoni, Alicia, et al.
Publicado: (2013)

Translating the role of PARP inhibitors in triple-negative breast cancer
por: Beniey, Michèle, et al.
Publicado: (2019)

PARP inhibitor resistance in breast and gynecological cancer: Resistance mechanisms and combination therapy strategies
por: Wang, Nannan, et al.
Publicado: (2022)

Gallotannin Imposes S Phase Arrest in Breast Cancer Cells and Suppresses the Growth of Triple-Negative Tumors In Vivo
por: Zhao, Tiejun, et al.
Publicado: (2014)

Immune Effect of Active Components of Traditional Chinese Medicine on Triple-Negative Breast Cancer
por: Zhao, Wenjie, et al.
Publicado: (2021)

Expanding the Use of PARP Inhibitors as Monotherapy and in Combination in Triple-Negative Breast Cancer
por: Yordanova, Mariya, et al.
Publicado: (2021)

Small Molecules, Inhibitors of DNA-PK, Targeting DNA Repair, and Beyond
por: Davidson, David, et al.
Publicado: (2013)

Wnt-pathway inhibitors with selective activity against triple-negative breast cancer: From thienopyrimidine to quinazoline inhibitors
por: Boudou, Cédric, et al.
Publicado: (2022)

Erratum: Wnt-pathway inhibitors with selective activity against triple-negative breast cancer: From thienopyrimidine to quinazoline inhibitors
por: Frontiers Production Office,
Publicado: (2023)

Structure-Based Design of 2-Aminopurine Derivatives as CDK2 Inhibitors for Triple-Negative Breast Cancer
por: Liang, Hanzhi, et al.
Publicado: (2022)

PARP inhibitors combined with radiotherapy: are we ready?
por: Sun, Chen, et al.
Publicado: (2023)

Inhibition of CXorf56 promotes PARP inhibitor-induced cytotoxicity in triple-negative breast cancer
por: Zhu, Ying, et al.
Publicado: (2023)

Editorial: Targeting triple negative breast cancer by natural compounds
por: Kumar, Shashank, et al.
Publicado: (2023)

Rad51 inhibition sensitizes breast cancer stem cells to PARP inhibitor in triple-negative breast cancer
por: Wang, Dong, et al.
Publicado: (2017)

Commentary: Adverse event profiles of PARP inhibitors: analysis of spontaneous reports submitted to FAERS
por: Schilder, Jeanne M., et al.
Publicado: (2023)

Efficacy and mechanism of the combination of PARP and CDK4/6 inhibitors in the treatment of triple-negative breast cancer
por: Zhu, Xiuzhi, et al.
Publicado: (2021)

Emerging Role of PARP Inhibitors in Metastatic Triple Negative Breast Cancer. Current Scenario and Future Perspectives
por: Barchiesi, Giacomo, et al.
Publicado: (2021)

SIK2 inhibition enhances PARP inhibitor activity synergistically in ovarian and triple-negative breast cancers
por: Lu, Zhen, et al.
Publicado: (2022)

Combining PARP inhibitors and platinum-based chemotherapy in metastatic triple negative and/or BRCA-associated breast cancer
por: Molto Valiente, Consolacion, et al.
Publicado: (2023)

Target Analysis and Mechanism of Podophyllotoxin in the Treatment of Triple-Negative Breast Cancer
por: Zhang, Wenfeng, et al.
Publicado: (2020)

Current landscape of personalized clinical treatments for triple-negative breast cancer
por: Zhang, Jun, et al.
Publicado: (2022)

Poly(ADP-Ribose)Polymerase (PARP) Inhibitors and Radiation Therapy
por: Jannetti, Stephen A., et al.
Publicado: (2020)

Evaluation of the Efficacy of PARP Inhibitors in Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis
por: Wu, Kan, et al.
Publicado: (2021)

Adverse events of bevacizumab for triple negative breast cancer and HER-2 negative metastatic breast cancer: A meta-analysis
por: Xun, Xueqiong, et al.
Publicado: (2023)

ZRANB1 is an NBS1 deubiquitinase and a potential target to overcome radioresistance and PARP inhibitor resistance in triple-negative breast cancer
por: Mei, Ying, et al.
Publicado: (2022)

SOX2 Promotes Cell Proliferation and Metastasis in Triple Negative Breast Cancer
por: Liu, Peng, et al.
Publicado: (2018)

Focus on Triple-Negative Breast Cancer: Potassium Channel Expression and Clinical Correlates
por: Lastraioli, Elena
Publicado: (2020)

Metabolomic Impact of Lidocaine on a Triple Negative Breast Cancer Cell Line
por: Chamaraux-Tran, Thiên-Nga, et al.
Publicado: (2022)

Palmatine Attenuates Metastatic Lung Colonization of Triple Negative Breast Cancer Cells
por: Ativui, Selase, et al.
Publicado: (2022)

Identification of PARP12 Inhibitors By Virtual Screening and Molecular Dynamics Simulations
por: Almeleebia, Tahani M., et al.
Publicado: (2022)

Auger Emitter Conjugated PARP Inhibitor for Therapy in Triple Negative Breast Cancers: A Comparative In-Vitro Study
por: Sankaranarayanan, Ramya Ambur, et al.
Publicado: (2022)

Synthetic lethality of PARP and NAMPT inhibition in triple-negative breast cancer cells
por: Bajrami, Ilirjana, et al.
Publicado: (2012)

Enhanced Antitumoral Activity of Encapsulated BET Inhibitors When Combined with PARP Inhibitors for the Treatment of Triple-Negative Breast and Ovarian Cancers
por: Juan, Alberto, et al.
Publicado: (2022)

Kinome-Wide siRNA Screening Identifies Src-Enhanced Resistance of Chemotherapeutic Drugs in Triple-Negative Breast Cancer Cells
por: Tzeng, Yen-Dun Tony, et al.
Publicado: (2018)

Efficacy and safety of PD-1 and PD-L1 inhibitors combined with chemotherapy in randomized clinical trials among triple-negative breast cancer
por: Qi, Yihang, et al.
Publicado: (2022)

Epigenetic Mechanism of 5-HT/NE/DA Triple Reuptake Inhibitor on Adult Depression Susceptibility in Early Stress Mice
por: Meng, Ping, et al.
Publicado: (2022)

Association Between BRCA Status and Triple-Negative Breast Cancer: A Meta-Analysis
por: Chen, Haixia, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_vuq8otoufjqdvichir6dqbt349